Skip to Content
  1. Authors
  2. Jeremy Glaser

Jeremy Glaser

Jeremy Glaser is the Markets Editor for


Much of the oft-cited tax efficiency of an ETF actually depends on the fund's underlying holdings and strategy, as well as how it's used by investors, says Morningstar's director of North American ETF research Paul Justice.

Valuations for pharmaceutical companies should rebound once investors look past today's patent expirations to tomorrow's new drugs, says Morningstar's Damien Conover.

Caught between a rock and a hard place, some packaged goods companies will try to roll out smaller, more frequent price increases to recoup rising input costs.

A new CEO, a $5 billion share-repurchase program, and a handful of promising new drugs make Pfizer shares look cheap even after today's runup, according to Morningstar's Damien Conover.

Overblown credit fears and several technical factors have created attractive opportunities in the municipal-bond market, says Nuveen Investments' John Miller.

With industrial orders rising, stabilization at GE Capital, and dispositions of non-core assets complete, General Electric is on track for a solid few years of results, says Morningstar's Daniel Holland.

Future dividend growth will be mostly determined by earnings and investor demand for yield, not changes to the tax code, says Morningstar DividendInvestor's Josh Peters.

Morningstar's Scott Burns would like to see more slicing and dicing on the fixed-income credit quality spectrum as well as an absolute return ETF.

Morningstar's Scott Burns expects to see continued fund flows into ETFs, more targeted fixed-income products, and growth in active and alternative funds in the coming year.

Morningstar's Maclovio Pina discusses an intriguing way to invest in a well-run Spanish bank while simultaneously mitigating Spanish macroeconomic risk.